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A B S T R A C T
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and
rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians
and public health staff with an updated and easy-to-consult document arising from consensus of Global
Tuberculosis Network (GTN) experts.
The core published documents and guidelines have been reviewed, including the recently published
MDR-TB WHO rapid advice and ATS/CDC/ERS/IDSA guidelines.
After a rapid review of epidemiology and risk factors, the clinical priorities on MDR-TB diagnosis
(including whole genome sequencing and drug-susceptibility testing interpretations) and treatment
(treatment design and management, TB in children) are discussed. Furthermore, the review
comprehensively describes the latest information on contact tracing and LTBI management in MDR-
TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB
sequelae, infection control and other public health priorities.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Multidrug-resistant (MDR-) and extensively drug-resistant
tuberculosis (XDR-TB) still represent a challenge for clinicians
and staff operating in national TB programmes (Akkerman et al.,
2019; Borisov et al., 2017, 2019; Lange et al., 2019, 2014; Nahid
et al., 2019; World Health Organization, 2019a, 2019b; Migliori and
Global Tuberculosis Network (GTN), 2019).
Although reviews on MDR-TB diagnosis, treatment, prevention
and rehabilitation have been recently published (Lange et al., 2014;
Lange et al., 2019), they are warranted by the rapid turnover of
recommendations and guidelines from the World Health Organi-
zation (WHO) (World Health Organization, 2019b) and scientific
societies (Nahid et al., 2019).
The aim of this review is to provide clinicians and public health
staff an updated and easy-to-consult document arising from
consensus of Global Tuberculosis Network (GTN) experts.Figure 1. How to design the regimen for multidrug-resistant tuberculosis.
In the text and figure we focus mainly on the ATS/CDC/ERS/IDSA guideline, as - although la
with main focus on low-TB incidence countries. Additional minor differences include le
regimen to drug-resistances identified, a larger number of drugs and a slightly differen
The 2019 WHO MDR-TB guidelines recommend that all 3 Group A drugs (bedaquiline, l
terizidone) are prescribed (4 versus 5 drugs recommended by ATS/CDC/ERS/IDSA guide
prescribed. If needed, Group C drugs (ethambutol, delamanid, pyrazinamide, imipen
prothionamide) should be administered.Methods
A non-systematic search of the literature was performed using
the key words ‘MDR-TB’/’XDR-TB’ to identify a minimum set of core
references from electronic databases (MEDLINE, PUBMED), existing
guidelines and grey literature. A writing committee composed of
internationally known experts was created, complemented by
experts from the members of the GTN (Treatment and Consilium
committees and other Committees’ chairs, see acknowledgements)
and consensus on the content was reached after multiple rounds of
revision (Akkerman et al., 2019; Borisov et al., 2019). WHO
definitions were used (e.g. MDR-/XDR-TB, treatment outcomes)
(Migliori and Global Tuberculosis Network (GTN), 2019; World
Health Organization, 2019a, 2019b). As this review is not aimed at
duplicating WHO and other existing guidelines, the GRADE
methodology (Nahid et al., 2019; World Health Organization,
2019b) was not used, and no formal recommendations are provided.rgely consistent with the 2019 WHO ones - they provide additional clinical elements
ss focus on injectables and the WHO shorter regimen, more focus on tailoring the
t prioritization of the drugs.
inezolid, levofloxacin/moxifloxacin) and 1 Group B drug (clofazimine, cycloserine/
lines). If only 1 or 2 Group A drugs are prescribed, both Group B drugs should be
em, meropenem, amikacin/streptomycin, para-aminosalycilic acid, ethionamide/
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on diagnosis, treatment and prevention of MDR-TB. The timing of
publication allowed the authors to capture the content of the WHO
rapid advice on MDR-TB (World Health Organization, 2019e) but
not of the new WHO MDR-TB guidelines (not yet released,
publication expected in early 2020). Therefore, the main focus was
on the ATS/CDC/ERS/IDSA guidelines (Nahid et al., 2019). The main
differences between the existing WHO guidelines and the above-
mentioned ones are summarized in the legend of Figure 1.
Epidemiology and risk factors
Elimination of TB by 2035 will only be possible if countries
address the emergence of drug-resistant (DR) strains of Mycobac-
terium tuberculosis effectively. According to the WHO 2018 report,
not all DR-TB cases are diagnosed (only 51% of people with
bacteriologically confirmed TB were tested for rifampicin resis-
tance (RR) in 2018), and not all DR-TB cases were treated (only one
in three of the approximately half a million people who developed
MDR/RR-TB in 2018 were treated). DR-TB continues to be an
important public health priority (World Health Organization,
2019d), and an estimated 19 million people are latently infected
with MDR-TB (Knight et al., 2019).
Prevention of DR-TB remains a key priority and cannot be
achieved by early diagnosis and appropriate treatment alone but
also requires preventive therapy and effective vaccination.
Moreover, the main risk factors for TB should be programmatically
addressed: these include poverty, overcrowding, HIV co-infection,
diabetes, alcoholism, smoking, immunosuppressive and other
drugs.
Diagnosis of MDR-TB
The End TB Strategy (World Health Organization, 2019d) calls
for the early diagnosis and treatment of all persons with any form
of drug-susceptible or DR-TB.
Successful diagnosis and treatment of MDR-/XDR-TB rely on
universal drug-susceptibility testing (DST) (Cabibbe et al., 2017;
Miotto et al., 2017; World Health Organization, 2019d). Increasing
access to early and accurate diagnosis using a WHO-recommended
rapid diagnostic test (WRD) (Table 1) is one of the main
components of the TB laboratory-strengthening efforts in the
End TB Strategy. In the recent years, the advent of rapid molecular
techniques, based on nucleic amplification tests (NAATs) and
sequencing have represented an important breakthrough in TB
diagnostics.
WHO approved High-throughput centralized MDR-TB tests
Four PCR-based platforms, suitable for high laboratory
throughput, have been approved by a WHO technical group
(World Health Organization, 2019c): (a) the RealTime MTB (Abbott,
Chicago, IL, United States of America [USA]); (b) the Roche Cobas
MTB assay (Roche, Basel, Switzerland), (c) the FluoroType MTBDR
assay (Hain Lifescience, Nehren, Germany) and (d) the BD Max
MDR-TB assay (Becton Dickinson, New Jersey, USA). Each platform
underwent a comparative analytical evaluation using a well-
defined M. tuberculosis strain panel to test their sensitivity for
detecting M. tuberculosis complex and their ability to detect key
mutations conferring resistance to rifampicin and isoniazid. There
are concerns that additional studies will be needed to verify the
specificity of the new assays, since they use multicopy or novel
DNA targets (or both) for the detection of TB. Therefore, a 2nd
phase of testing will evaluate the clinical validity of the assays
through testing of the platforms in up to 3 national reference
laboratories in high TB burden settings. The results will becompared with the reference standards of culture, phenotypic DST,
Xpert MTB/RIF Ultra and molecular sequencing.
Next-Generation sequencing (NGS): a promising tool
NGS is rapidly gaining interest as an affordable all-in-one
diagnostic solution that allows for individualised treatment. Unlike
other TB diagnostic technologies providing partial information
on drug-susceptibility limited by a set of resistance mutations,
NGS gives comprehensive genetic information with a variety of
applications ranging from diagnosis to surveillance of DR-TB.
Current generation sequencing technology relies on DNA extrac-
tion from clinical samples or clinical isolates, library preparation
made by collection of fragmented DNA with oligonucleotide
adaptors, sequencing and data analysis. Despite the invaluable
application of NGS, implementation of this technology has been
hampered, among other causes, by high costs of equipment, need
for technical training and guidance for clinical interpretation of
generated data. The WHO has recently released a guide providing a
comprehensive overview of workflow and equipment, principles
to best interpret genetic data, experience in using NGS in
population-based studies and, lastly, requirements for implemen-
tation in low- and middle-income countries. However, although
promising, NGS will still need to achieve stringent regulatory
approval, such as from the WHO, to facilitate its implementation
into routine diagnostics (World Health Organization, 2018a).
How to interpret DST
WHO (World Health Organization, 2018b) defines universal
access to DST as rapid determination for at least rifampicin, and
further DST for at least fluoroquinolones among all RR-TB patients.
Culture-based phenotypic DST methods are currently the gold
standard for DR-TB detection, but these methods are time-
consuming, and require sophisticated and well established
laboratory infrastructure, qualified staff and strict quality and
infection control. In addition, for some drugs (fluoroquinolones,
rifampicin) molecular tests could be more predictive than
phenotypic tests. Traditionally, DST for M. tuberculosis has relied
on the testing of a single, critical concentration (CC), which is used
to differentiate resistant from susceptible isolates of M. tuberculosis
and is specific for each anti-TB agent and test method. Laboratory
DSTs to anti-TB agents serve four main purposes: (1) to guide the
choice of an effective regimen; (2) to confirm that DR has emerged
when a patient has failed to show a satisfactory response to
treatment; (3) can be used for surveillance of emerging DR;
(4) may guide management of close contacts of the DR-TB cases,
including children.
Use of microtitre plates to determine minimal inhibitory
concentrations (MICs) to multiple drugs at the same time is an
appealing technology and could be usefully adopted to monitor
increase of MIC in a population exposed to new drugs. WHO will
release CC on microtitre plates in 2020.
To perform phenotypic DST, mycobacteria are often initially
grown in a variety of solid or liquid culture media. Bacterial growth
on solid medium can be identified visually (i.e. by identifying
characteristic growth) or by automated detection of fluorescence
in liquid medium. The MGIT (mycobacterial growth indicator tube)
automated M. tuberculosis culture system (Becton Dickinson
Diagnostic Systems, Sparks, MD, USA) indicates a reduction in
the oxygen tension to confirm the detection of “M. tuberculosis
complex” (MTBC) and excludes the presence of any nontuberculous
mycobacteria or other bacteria prior to performing DST.
WHO recommends the use of rapid molecular DST as the initial
test to detect DR prior to the initiation of appropriate therapy for all
TB patients, including new and previously treated ones.
Table 1
New TB diagnostics development pipeline (adapted from World Health Organization, 2019d).
NEW TB DIAGNOSTICS
TECHNOLOGIES ENDORSED BY WHO
Molecular detection of TB and drug resistance
– Xpert MTB/RIF and Xpert Ultra as the initial diagnostic test for TB and rifampicin resistance, Cepheid, USA
– Line probe assays for the detection of M. tuberculosis (MTB), isoniazid and rifampicin resistance in acid-fast bacilli smear positive sputum or MTB cultures (FL-LPA), Hain
Lifescience, Germany and Nipro, Japan
– TB LAMP for detection of TB, Eiken, Japan
Nonmolecular technologies
– Interferon gamma release assay (IGRAs) for the diagnosis of latent TB infection (LTBI) Oxford Immunotec, UK; Qiagen, USA
Culture-based technologies
– Commercial liquid culture systems and rapid speciation
– Culture-based phenotypic DST using 1% critical proportion in LJ,7H10,7H11 and MGIT media.
Microscopy
– Light and light-emitting diode microscopy (diagnosis and treatment monitoring)
Biomarker (MTB antigen) based assays
– Alere Determine TB-LAM, Alere, USA (TB detection in people seriously ill with HIV)
ON THE MARKET (NOT SUBMITTED TO WHO FOR EVALUATION)
Molecular detection of TB and drug resistance
– iCubate System, iCubate, USA
– Genechip, TB drug resistance array, Capital Bio, China
– EasyNAT TB Diagnostic kit, Ustar Biotechnologies, China
TECHNOLOGIES UNDER DEVELOPMENT
Molecular detection of TB and drug resistance
– Gendrive MTB/RIF ID, Epistem, UK
– Xpert XDR-TB cartridge, Cepheid, USA
– TruArray MDR-TB, Akkoni, USA
– INFINITIMTB Assay, AutoGenomics, USA
– FluoroType XDR-TB assay, Hain Lifescience, Germany
– MeltPro TB assay, Zeesan Biotech, China
– QuantuMDx, POC, UK
Tests for latent TB infection
– Diaskin test, Generium, Russian Federation
– C-Tb test, Serum Institute of India, India
SCHEDULED FOR WHO EVALUATION IN 2019/2020
Molecular detection of TB and drug resistance
– Molecular technologies for genotypic drug resistance testing (including sequencing technologies)
– FluoroType MTBDR, Hain Lifescience, Germany
– m2000 RealTime MTB System, Abbott, USA
– BD Max MDR-TB, Becton Dickinson, USA
– Roche cobas1 MTB system, Roche Diagnostics, Basel, Switzerland
Radiology
– Computer aided detection (CAD)
WHO POLICY UPDATES SCHEDULED FOR 2019/2020
Molecular detection of TB and drug resistance
– Xpert MTB/RIF Ultra for detection of TB and rifampicin resistance in pulmonary, extrapulmonary and paediatric samples, Cepheid, USA
– Truelab/Truenat MTB, Molbio/bigtec Diagnostics, India
Culture-based drug susceptibility testing
– SensititreTM MYCOTBI plate; ThermoFisher Scientific Inc., USA
MDR-TB: multidrug-resistant tuberculosis; XDR-TB: extensively drug-resistant tuberculosis; IGRAs: interferon-gamma release assays; LTBI: latent tuberculosis infection;
TB-LAM: tuberculosis lipoarabinomannan assay.
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isoniazid, fluoroquinolones and amikacin should be performed
promptly to inform which second-line drugs can be used for the
treatment of RR-TB, MDR-TB and XDR-TB.
Genotypic DST methods such as NGS are attractive alternatives
to culture-based DST methods given the rapidity and the detailed
sequence information that can be generated for multiple gene
regions associated with DR. However, until our knowledge ofthe molecular basis of resistance improves, culture-based DST
for other important second-line drugs including bedaquiline,
linezolid, and other agents will still need to be performed. One
should consider performing culture-based DST for fluoroquino-
lones and amikacin only when resistance is suspected despite the
absence of previously identified genetic mutations associated with
DR to these medicines, as commercially available rapid genetic
methods such as the second-line line-probe assays detect
G.B. Migliori et al. / International Journal of Infectious Diseases 92S (2020) S15–S25 S19approximately 85% of fluoroquinolones- or two thirds of amino-
glycoside resistance mutations.
Determining critical concentrations for DST
DST results should be able to clearly differentiate between
susceptible and resistant, and should help physicians prescribe
effective anti-TB therapy. DST for second-line anti-TB agents
should be built on the foundation of reliable, quality-assured first-
line DST. In 2018, critical concentrations were revised or
established for performing DST for the WHO Group A drugs that
are strongly recommended in the treatment of DR-TB. These
include the later-generation fluoroquinolones (levofloxacin and
moxifloxacin), bedaquiline, and linezolid. A critical concentration
for the oral core agent clofazimine was established for MGIT
medium only. Critical concentrations for the Group C (add on)
agents were established or validated for delamanid, amikacin, and
pyrazinamide. Knowledge of pyrazinamide susceptibility can
inform decisions on the choice and design of effective DR-TB
regimens. Culture-based pyrazinamide phenotypic DST is difficult
to perform and can produce unreliable results. Currently, BACTEC
MGIT 960 liquid culture method is the only WHO-recommended
method for pyrazinamide DST, even though a high rate of false-
positive resistance results has been reported in some laboratories.
In a quality-assured laboratory, pyrazinamide DST in MGIT can
be performed reliably and reproducibly. The lack of WHO-
recommended molecular test to diagnose pyrazinamide resistance
ahead of treatment start implies that even where pyrazina-
mide DST is available, the results usually only become accessible
after treatment has been initiated. The detection of resistance-
conferring mutations in the pncA gene using DNA sequencing is
the most reliable method for rapid detection of pyrazinamide
resistance although there is emerging evidence of mutations other
than pncA conferring pyrazinamide-resistance.
Treatment for MDR-TB is increasingly becoming more
individualised as a result of innovations in diagnostics and
growing scientific understanding of the molecular basis for DR
and the pharmacokinetics and pharmacodynamics of TBFigure 2. Clinical management of patients with multidrug-resistant tuberculosis.
MDR-TB: multidrug-resistant tuberculosis; WGS: whole genome sequencing; LPA: line p
PTH: ethionamide/prothionamide; PAS: para-aminosalicylic acid; LZD: linezolid; QTc int
the T wave in the heart’s electrical cycle; BDQ bedaquiline; CFZ: clofazimine; DLM: demedicines. Availability of new NGS-based tests able to detect
mutations associated to DR on multiple targets makes it possible
to predict resistance to first- and second-line drugs from smear
positive clinical samples. Two signals are clear from the current
scientific evidence assessment: (a) the feasibility of effective and
full-oral treatment regimens for most patients; (b) the need to
ensure that pre-XDR and XDR are excluded (at least to the
fluoroquinolones and amikacin) before starting patients on
treatment, especially for the shorter MDR-TB regimen. When
countries switch to all-oral regimens, the need to exclude
resistance to amikacin will be less useful.
DST should be performed at the time of treatment initiation
(Figure 2) against the drugs for which a reliable method is
available. If baseline DST is not possible, DST should be performed
on the first positive culture isolated from the patient during
treatment monitoring. Positive cultures isolated from patients
during treatment monitoring should be stored frozen in glycerol. If
DR or treatment failure is suspected, phenotypic DST and NGS, if
available, should be performed to collect data on mutations that
may be associated with TB DR, especially for the newer drugs.
In response to this challenge, high-TB burden countries must
upgrade and streamline their laboratory networks. Molecular
techniques should replace phenotypic methods for initial diagno-
sis and detection of DR, while traditional cultures will still be
needed during follow-up to detect viable bacilli. At least at central
level capacity to perform DST for bedaquiline, linezolid, clofazi-
mine and delamanid should be established. The Xpert system
should be introduced at point-of-care facilities for rapid detection
of RR, and Line Probe Assays (LPAs) can diagnose MDR-TB and
XDR-TB in just a couple of days, allowing for the early institution of
effective treatment.
How to design the regimen
A patient-tailored clinical strategy focused on good adherence
is necessary to achieve high treatment success rates for MDR-TB
patients (Figures 1 and 2,Table 1). In particular, the need to
individualize treatment regimens has been recently emphasized,robe assay; DST: drug-susceptibility testing; DOT: directly observed therapy; ETH/
erval: corrected measure of the time between the start of the Q wave and the end of
lamanid.
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strain.
Treatment success depends on the ability of the treating team to
monitor and manage adverse events and concomitant comorbid-
ities (e.g., HIV-infection, diabetes mellitus, alcoholism, etc.),
potential drug-drug interactions, patient’s preferences and tolera-
bility (e.g., administration of second-line injectable drugs) in
addition to designing an effective treatment regimen (Akkerman
et al., 2019; Borisov et al., 2019; Nahid et al., 2019; World Health
Organization, 2019b). In individuals with pauci-bacillary disease
(e.g., children, HIV co-infected individuals) and without the
confirmation of a specific DST pattern, the regimen should be
tailored to the DST findings of the potential index case or the MDR-
TB epidemiology of the geographical area where the patient
resides (Nahid et al., 2019).
However, as designing the regimen and managing the MDR-TB
patient is difficult, a multi-disciplinary approach is recommended,
assisted by a MDR-TB Consilium, MDR-TB cohort or equivalent
expert support. In addition to regional and national TB Consilia, a
supranational cost-free and multilingual platform is available
offering validated and vetted advice in clinical management,
within 48 h (Global TB Consilium: http://www.waidid.org/site/
workinggroups). According to the ATS/CDC/ERS/IDSA guidelines
the regimen should include five drugs during the intensive phase
and four drugs during the continuation phase (Nahid et al., 2019),
with a treatment duration between 15 and 21 months after culture
conversion for MDR-TB and between 14 to 24 months for pre-XDR/
XDR-TB patients (Nahid et al., 2019). The intensive phase (aimed at
significantly decreasing the bacillary burden) should range from 5
to 7 months (Nahid et al., 2019) after culture conversion according
to the same document.
According to the consolidated WHO MDR-TB guidelines (World
Health Organization, 2019b), 4 oral drugs are recommended in the
intensive phase and at least 3 in the continuationphase of treatment,
with a total treatment duration of 18–20 months for most patients.
In MDR/RR-TB patients on longer regimens, a treatment duration of
15–17 months after culture conversion is suggested for most
patients, with an intensive phase of 6–7 months when the longer
regimen includes amikacin or streptomycin: the treatment dura-
tions mentioned above may be modified according to the patient’s
response to therapy (World Health Organization, 2019b).
Six consecutive steps are recommended (Figure 1) by the
recent ATS/CDC/ERS/IDSA guidelines, published in 2019. Step one
implies the prescription of one later-generation fluoroquinolone
(i.e., levofloxacin, moxifloxacin), followed by (Step 2) two high-
priority drugs (i.e., bedaquiline and linezolid). Step 3 includes
two other highly effective drugs (i.e., clofazimine, cycloserine).
The need for Step 4 depends on the strain’s susceptibility
pattern: in case of DR to one or more of the above-mentioned
drugs and the impossibility to have 5 active drugs we need to
choose one injectable drug (amikacin or streptomycin). If needed
or a full oral regimen is preferred, injectables should be replaced
by delamanid, pyrazinamide, or ethambutol (Step 5: the last two
medicines only if confirmed susceptibility  to these agents). A
complicated DR pattern preventing the prescription of a 5-drug
regimen based on the above-mentioned medicines implies the
need for different agents (Step 6). The ATS/CDC/ERS/IDSA
guidelines assign lower priority to the administration of
ethionamide/prothionamide, imipenem/meropenem plus clav-
ulanate, para-aminosalycilic acid, high-dose isoniazid, based on
their poor effectiveness to decrease mortality or inability to
increase the treatment success rate, or route of administration
(Nahid et al., 2019). Capreomycin, kanamycin, macrolides, and
amoxicillin/clavulanic acid (the latter should only be adminis-
tered with a carbapenem-containing regimen) are no longer
recommended (strong recommendation).With regard to injectables, they require more time to prepare,
administer, and monitor; consume patient and staff time; are less
liked by patients; and invariably raise costs. Amikacin is an
effective drug against DR tuberculosis as demonstrated in previous
IPD metanalyses. However, it has been replaced by more effective,
oral and less toxic medications; this does not mean that it cannot
be useful in settings where it can be administered and monitored
safely. Recently published and unpublished experiences suggest
carbapenems are effective in patients with complex resistance
profiles (Arbex et al., 2016; The Collaborative Group for the Meta-
Analysis of Individual Patient Data in MDR-TB treatment-2017
et al., 2018; Tiberi et al., 2016a, 2016b).
Clinical management
As the clinical management of MDR-TB patients is complicated
(Figure 2), an adequately planned management model balancing
available specialized resources and prevalence of disease is
required. Thus, in countries with low prevalence and high
resources (e.g. Western European countries, North America) it
should ideally be carried out in MDR-TB reference centres, where
skilled clinicians can operate in the presence of adequate
infrastructure and pathways (infection control, palliative care,
quality-controlled laboratory, access to cohort and consilium
advice) (Migliori et al., 2019). Conversely, in settings with limited
resources and high prevalence of MDR-TB a decentralized model of
care has proven to be effective, and is advisable (Loveday et al.,
2018). In this latter case, only complicated cases are referred to
specialized centres or proposed to local/international TB consilia.
Details on the use of molecular testing and DST as well as on the
principles to design an effective regimen treatment duration are
provided in Figures 1 and 2 and in the previous sections (Nahid
et al., 2019; World Health Organization, 2019b).
Treatment design should be based only on proven or highly
probable drug susceptibility, ‘in-vitro’ or based on clinical and
epidemiological information (e.g., the DR pattern of the index
patient, or the most updated epidemiological data on the prevalent
drug resistances in a specific setting).
Given the relative difficulty and cost of sampling patients on a
weekly basis and the lack of approved biomarkers, duration of
treatment continues to be an amalgamation of clinical and
radiological data, a lack of positive microbiology, and erring on
the side of caution.
More research is necessary to give a final verdict on the efficacy/
effectiveness of standardized shorter-course regimens lasting 12
months in comparison with effective longer all-oral regimens
(Nahid et al., 2019). It is possible that the use of new drugs,
particularly in some forms of pauci-bacillary or extrapulmonary TB
might require, in the future, shorter regimens than more severe
cavitary forms; however, more data is needed to dictate shorter
durations of treatment.
WHO recommends the use of shorter 9–12 month regimens
(4–6 months with amikacin-moxifloxacin-ethionamide[prothio-
manide]-clofazimine-pyrazinamide-high dose isoniazid/etham-
butol/5 months with moxifloxacin-clofazimine-pyrazinamide-
ethambutol) when the DR pattern is not complicated based on
the findings of the STREAM trial (Nunn et al., 2019). This should be
used only for the regimens including injectables, but after a recent
literature review, WHO has updated recommendations and is now
phasing out the shorter injectable-containing regimens and
recommending a shorter all-oral bedaquiline-containing regimen
for eligible MDR/RR-TB patients under specific conditions (World
Health Organization, 2019e). However, due to the long half-life of
bedaquiline, patients started on an all-oral regimen lost to follow-
up may be exposed to potential bedaquiline monotherapy, with a
potential risk of developing DR. Recent evidence suggests that
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mizes adverse events (Borisov et al., 2017; Piubello et al., 2020).
Following the results of the NIX TB trial (World Health
Organization, 2019e) and the US FDA (Food and Drug Administra-
tion) approval in patients with XDR-TB, a shorter regimen with
bedaquiline, pretomanid and linezolid (BPaL regimen) may be used
(under operational research conditions and no previous use of
bedaquiline and linezolid) as an alternative to the longer regimen.
If pretomanid-containing regimens are used under operational
conditions, capacity to test for the drug should be equally
considered.
In selected patients with strong risk of relapse and treatment
failure (and localised pulmonary sequelae), elective partial lung
resection (e.g., lobectomy or wedge resection) has been recom-
mended in addition to an adequately designed MDR-TB regimen
(Nahid et al., 2019).
During follow-up close monitoring of the treatment response is
recommended: patients should be assessed clinically (symptoms
and clinical signs recovering, including weight gain for children),
radiologically, and bacteriologically (culture positivity evaluated
monthly). In the case of culture remaining positive after three
months of treatment, phenotypic DST should be repeated to detect
if new DR has occurred (Nahid et al., 2019). When drug-susceptible
DST does not match with the patients’ clinical progress, underlying
DR or malabsorption can be responsible, and further investigations
like therapeutic drug monitoring (TDM) might be necessary.
During follow-up visits, patients should thoroughly be ques-
tioned about the occurrence of drug-related adverse events: they
could decrease patient’s adherence, increasing the probability of
new DR. Adverse events should be notified to the national
programme, ideally within a comprehensive aDSM (active drug-
safety monitoring and management) system (Akkerman et al.,
2019; Borisov et al., 2019).
TDM is helpful to detect low drug exposure in case of lack of
response or drug-related adverse events (Nahid et al., 2019). Based
on the measured drug concentration, drug dosages can be adapted
to optimize the treatment. Proactive use of TDM can help to
prevent drug-related complications in patients with risk factors for
either low or high drug exposure (Nahid et al., 2019; World Health
Organization, 2019b). TDM has been recommended for patients
with gastrointestinal problems (e.g. affecting absorption of the
drug), renal or hepatic problems (e.g. low clearance of the drug),
comorbidities like diabetes type2 and HIV or drug-drug inter-
actions (Nahid et al., 2019). For the maximum benefit, samples for
TDM need to be collected at the right time and in the right manner,
analyzed in a timely fashion and correctly interpreted, resulting in
a dose adjustment recommendation to the clinician (Alffenaar
et al., 2019). Clearly, a good understanding of bioanalytical
procedures and clinical pharmacologically is required to develop
a TDM for a programmatic setting (Alffenaar et al., 2019). The use of
different sampling strategies like saliva and dried blood spot in
addition to plasma or serum will allow a simple semi-quantitative
screening to detect low drug exposure as well as precise TDM in
those with detected low exposure (Alffenaar et al., 2019b, 2019a).
A patient-centered approach is recommended after the
diagnosis of MDR-TB, as suggested by the WHO End TB Strategy
in its first pillar (World Health Organization, 2015a; World Health
Organization, 2019d). Clinicians should clearly explain the risks
associated with the disease (e.g., transmission of M. tuberculosis
strains in case of inappropriate therapy), and with the therapy (e.g.,
potential occurrence of adverse events, importance of adherence to
treatment). Patients should be actively involved in the choice of the
drug regimen (use of injectable-containing versus full-oral
regimen), and in the management of concomitant comorbidities
and potential drug-drug interactions (Nahid et al., 2019; World
Health Organization, 2019b).The time-span of isolation of MDR/XDR patients is often a
matter of debate in TB consilia, and unequivocal guidelines for de-
isolation of patients in general are missing (Petersen et al., 2017).
WHO and CDC guidelines may be interpreted as requiring MDR-TB
patients to be isolated as long as they are culture-positive, but the
recent consensus document from WHO Europe has reviewed the
literature extensively and has shown the importance of effective
treatment for duration of isolation (Migliori et al., 2019). Sputum
may be culture-positive for 1-2 months after treatment initiation
(Fitzwater et al., 2010) and afterwards there is a 2-month delay for
the culture result to come out as negative, unless liquid cultures are
in use, implying 3-4 months of isolation, perhaps hospitalization.
Yet, also some MDR-TB patients are no longer infectious after
2 weeks of effective treatment (Dharmadhikari et al., 2014),
although special caution should be taken in case of highly smear-
positive cases – as in cavernous disease (Dharmadhikari et al.,
2014; Imperial et al., 2018; Menzies, 1997; Petersen et al., 2017;
Migliori et al., 2019). These patients remaining infectious as long as
they are sputum smear or culture positive seems to be unfounded,
and although MDR-TB patients remain culture-positive longer
(Telzak et al.,1997), this is a result of being on ineffective treatment
initially. Once an effective treatment has been established, MDR-TB
patients are also likely to reduce infectiousness rapidly. Therefore,
3–4 months of isolation is not warranted (Petersen et al., 2017;
Rouillon et al.,1976) while isolation beyond 2 weeks of treatment is
warranted because of the risk of non-effective treatment since full
susceptibility results may not be available at the time of treatment
initiation. New RNA-based molecular tests may in the future be
used to monitor infectiousness and response to treatment without
the delay linked to the use of culture.
Management of children with MDR-TB
Given the difficulty of microbiological confirmation in children,
MDR-TB is often a presumptive diagnosis, although microbiolog-
ical confirmation should always be pursued. Use of the new Xpert
Ultra is advised in children given increased sensitivity in patients
with pauci-bacillary disease. (Zar and Nicol, 2019). Children
diagnosed on clinical grounds, following recent (in the past 12
months) close contact with an infectious MDR-TB source case,
should be treated according to the DST results of the likely source
case. The principles of treatment are similar to those articulated for
adults, but the rationale for using injectable-free regimens is even
stronger given the devastating consequences of hearing loss in
early life (Seddon et al., 2018). Although the same drugs used
in adults are used in older children, bedaquiline is currently not
advised in children less than 6 years of age (<15 kg) given the
absence of pharmacokinetic and safety data (The Sentinel Project
for Pediatric Drug-Resistant Tuberculosis, 2018). Bedaquiline may
be replaced by delamanid in children 3-6 years of age, but cannot
be given to children <3 years of age (<10 kg) for the same reason
(Huynh and Marais, 2019; World Health Organization, 2016). In
young children (<3yrs of age) alternative second-line drugs should
be considered (Schaaf et al., 2018). Children with pauci-bacillary
disease may sometimes be treated for a shorter duration
(19–15 months) if an adequate regimen is given, and the treatment
response is good and is well tolerated. Child-friendly drug
formulations should be used whenever possible, and all relevant
co-morbidities, such as HIV co-infection and malnutrition,
considered and addressed. In children with MDR-TB meningitis,
careful consideration should be given to central nervous system
and cerebrospinal fluid penetration of the various drugs (Huynh
et al., 2019). With optimal management, excellent outcomes have
been reported in children with MDR and even XDR-TB (Harausz
et al., 2018).
Table 2
Evidence of treatment of latent tuberculosis infection in contacts of multidrug-resistant tuberculosis.
Study/trial Study population/Aim Design/treatment Adverse events and outcome Reference
TrialTB-
CHAMP
Household MDR TB contacts; only children
< 5 years old – South Africa (enrolling)
Aim: To evaluate the efficacy of
levofloxacin vs. placebo for prevention of
MDR-TB in young children following
household exposure
Multi-centre, randomized double blind
placebo-controlled trial
6 months of parent-administered oral
levofloxacin once per day, vs 6 months of
placebo in the control group; followed for 18
months after treatment completion
Not reported WHO International
Clinical Trials Registry
Platform, identifier:
ISRCTN92634082
TrialPHOENIx
MDR-TB
Household MDR TB contacts; all ages –
multiple countries (enrolling)
Aim: To evaluate the protective effect
delaminid vs. isoniazid for prevention of
M/XDR-TB following household exposure
Unblinded, randomized comparative trial
Compare efficacy and safety of 26 weeks of
delamanid versus 26 weeks of isoniazid for
preventing confirmed or probable active TB
during 96 weeks of follow-up among high-
risk household contacts of M/XDR-TB adults
Not reported ClinicalTrials.gov
identifier:
NCT03568383
V-QUIN MDR
TRIAL
Household MDR TB contacts; all ages –
Vietnam (completed enrolling)
Aim: To evaluate the efficacy of
levofloxacin vs. placebo for prevention of
MDR-TB following household exposure
Double-blind parallel group RCT
6 months of self-administered oral
levofloxacin once per day, vs 6 months of
placebo in the control group; followed for at
least 24 months after treatment completion
Not reported <**Australian New
Zealand Clinical Trials
Registry (ANZCTR),
identifier:
ACTRN12616000215426
Meta-analysis Meta-analysis of treatment of LTBI using
PICO questions following Cochrane
procedures
To assess whether treatment of LTBI from
MDR-TB contacts is significantly associated
with lower tuberculosis incidence,
compared with no medical treatment
The most effective regimen included a
fluoroquinolone combined with
ethionamide
The most cost-effective regimen included
fluoroquinolone/ethambutol, followed by
fluoroquinolone alone, then by
pyrazinamide/ethambutol
Pyrazinamide regimens reported
up to 66% adverse events
The regimen was considered cost-
effective.
Marks et al. (2017)
Case series of
close MDR-
TB contacts
Prevent development of clinical MDR-TB Fifty contacts of HIV- and MDR-TB patients
treated with moxifloxacin; 30 patients
completed the regimen in New York City
Three discontinued treatment
because of gastrointestinal
symptoms.
Trieu et al. (2015)
Case series of
close MDR-
TB contacts
Twelve consecutive contacts to an MDR TB
case
The aim of the study was to describe the
adverse events related to combined
pyrazinamide and ethambutol to treat LTBI
Observational case series, The regimens
consisted of pyrazinamide (23  4 mg per Kg
BW) and ethambutol (17  4 mg per Kg BW)
Treatment was discontinued in
seven cases (58%) after a median of
119 days, due to hepatotoxicity in
six cases (ALT or AST elevation more
than four times the upper normal
limit), and gastrointestinal
symptoms in one case
Younossian et al.
(2005)
Open label,
comparative
study
186 children were included as contacts of
164 MDR-TB source patients
They underwent 12 months follow-up in
South Africa
Ofloxacin (15–20 mg/kg BW daily plus
ethambutol (20–25 mg/kg BW daily), or
isoniazid (15–20 mg/kg BW daily) for
6 months
7 (3.7%) children developed grade 3
adverse events
One child died and 6 developed
active TB (of whom 5 had poor
adherence)
Seddon et al. (2013)
Case series of
close MDR-
TB contacts
119 contacts of MDR-TB patients were
followed-up in Micronesia
Of the 104 who initiated treatment, 93
(89%) completed the regimen
None receiving treatment developed active
TB.3 of 15 contacts who refused and 15
unidentified contacts developed MDR-TB
When M. tuberculosis strains were resistant
to isoniazid, rifampicin and ethambutol the
regimens were as follows: Adults aged >12
years received oral moxifloxacin 400 mg
daily and ethambutol 15 mg/Kg BW daily for
12 months Children aged 12 years received
oral levofloxacin 20 mg/Kg BW daily and
ethambutol 15 mg/Kg BW daily for 12
months When M. tuberculosis strains were
resistant to isoniazid, rifampicin,
pyrazinamide, ethambutol and
streptomycin the regimen included:
Adults aged >12 years: oral moxifloxacin
400 mg daily for 12 months;
Children aged 12 years: oral levofloxacin
20 mg/kg BW daily and oral ethambutol 20
mg/kg BW daily for 12 months
4 contacts discontinued due to
adverse events
Bamrah et al. (2014)
Case series
close MDR-
TB contacts
Prevent development of TB after exposure
to an MDR-TB index patient
31 children with LTBI after exposure, 26
treated with levofloxacin and pyrazinamide
12 children required treatment
changes because of adverse events.
Adler-Shohet et al.
(2014)
Case series
(retrospective
audit of
paediatric
management)
The audit identified between 2006 and
2010 23 children in 6 centres of England
who were contacts of confirmed MDR-TB
index cases
Of 23 children, 8 were non-infected and 12
with confirmed LTBI, 8 (66.7%) were treated
with 2 drugs for a median of 6 months
(range 6-12 months) based of the drug-
susceptibility pattern of the index case. No
details of the regimes are provided
All 12 children (including the 10
who completed the 24 month
follow-up) were well and did not
report adverse events or TB
Williams et al. (2013)
Case series Occupational exposure to MDR TB resistant
to rifampicin, isoniazid, streptomycin, and
ethambutol in New York City
Sixteen health care workers entered a
six-month investigational trial of ofloxacin
(800 mg a day) and pyrazinamide
(1500 mg a day)
14 cases discontinued LTBI
treatment after less than 6 months;
13 reported one or more adverse
events, including arthralgia (7),
gastrointestinal distress (6) and
hepatitis
Horn et al. (1994)
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Table 2 (Continued)
Study/trial Study population/Aim Design/treatment Adverse events and outcome Reference
Case series Seventeen individuals with
presumed LTBI MDR-TB infection
Treated with pyrazinamide
and levofloxacin
Fourteen individuals developed
musculoskeletal adverse events
(11 probably related to combination
therapy) and 8 central nervous ones
Hyperuricemia, gastrointestinal
and dermatological effects were
also common.Therapy was
discontinued in all of them
Papastavros et al.
(2002)
MDR-TB: multidrug-resistant tuberculosis; LTBI: latent tuberculosis infection; PICO: population, intervention, comparison, and outcome; ALT-AST: alanine amino transferase
and aspartate amino transferase; BW: body weight.
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MDR-TB contacts
While rates of DR-TB are proportionately higher in persons
previously treated for TB, the burden of MDR-TB is larger in persons
who have never been treated for TB, a consequence of transmission
of DR bacilli in the community. Thus, 54% of MDR-TB occurs among
patients who had never received TB treatment (Kendall et al.,
2015). In one study 7.8% of household contacts of MDR-TB patients
developed TB, mostly occurring within one year of index case’s
diagnosis (Shah et al., 2014). Until recently, there was no consensus
to provide preventive treatment to contacts of infectious MDR-TB
patients, but this has changed in the new ATS/CDC/ERS/IDSA
Clinical Practice Guideline (Nahid et al., 2019). A systematic review
on 21 relevant papers found that the estimated MDR-TB incidence
reduction was 90% with preventive treatment (Marks et al., 2017).
Hence, preventive treatment of MDR-TB contacts with LTBI is
currently recommended based on the above observation.
Several randomised clinical trials are currently ongoing to
determine a single-drug preventive treatment regimen for MDR-
TB contacts; these are the PHOENIx trial (delamanid versus
isoniazid) and the V-QUIN and TB- CHAMP clinical trials (levo-
floxacin versus placebo in adults and children, respectively). While
results of these trials are awaited, preventive treatment should be
determined on the basis of the DST results of the source-case’s M.
tuberculosis isolate.
If possible, a later-generation fluoroquinolone alone or with a
second drug such as ethambutol should be used (Nahid et al.,
2019). Pyrazinamide should not be used as the second drug,
because of higher adverse events and discontinuations. The
evidence available is summarised in Table 2. (Adler-Shohet
et al., 2014; Bamrah et al., 2014; Horn et al., 1994; Marks et al.,
2017; Papastavros et al., 2002; Seddon et al., 2013; Trieu et al.,
2015; Williams et al., 2013; Younossian et al., 2005).
Functional evaluation and rehabilitation post-TB
Recent evidence shows that about half of pulmonary TB
patients completing treatment suffer from the consequences of
sequelae with obstructive, restrictive and mixed functional
patterns (Muñoz-Torrico et al., 2016; Tiberi et al., 2019).
The extent of pulmonary sequelae is likely to be associated with
initial bacterial burden, extent of inflammation and the accompa-
nying duration of treatment, being more important among MDR-/
XDR-TB patients (especially if they had prior episodes of TB) than
among drug-susceptible ones (Muñoz-Torrico et al., 2016; Tiberi
et al., 2019).
A complete post-TB treatment functional evaluation has
been recommended including radiology, spirometry with bron-
chodilator response, assessment of lung volumes (plethysmog-
raphy), carbon monoxide diffusion capacity of the lung (DLCO),
arterial blood gases analysis; 6-min walking test (6MWt) andquality of life evaluation (Muñoz-Torrico et al., 2016; Tiberi et al.,
2019).
Pulmonary rehabilitation proved to be effective in improving
the above-mentioned parameters (Spruit et al., 2013; Visca et al.,
2019). Further research is necessary to identify setting-specific
models and programmatic feasibility of these interventions
(Muñoz-Torrico et al., 2016; Spruit et al., 2013; Tiberi et al.,
2019; Visca et al., 2019).
Public health management
The principles of public health management are centered
around achieving high success rates when treating drug-suscepti-
ble cases and trying to diagnose and cure the highest possible
proportion of cases with MDR-TB while preventing further
transmission within the community (Pontali et al., 2013).
The importance of administrative and environmental control
measures as well as of personal protection (masks for infectious
patients and respirators to protect health care workers and visitors
from potential infections) has been recently emphasised (Migliori
et al., 2019; Migliori et al., 2018; World Health Organization, 2019).
WHO strongly advocates for a reduction of unnecessary admissions
of MDR-/XDR-TB cases which need to be limited to severe cases
with life-threatening conditions, adverse events and co-morbid-
ities, while reducing as much as possible admission for ‘social
reasons’ (Migliori et al., 2019; Migliori et al., 2018; World Health
Organization, 2019). Recent WHO European guidance provides
criteria for units admitting infectious cases, including the
availability and necessary standards of infection control measures,
quality-controlled laboratory services, adequately trained staff and
palliative care service, among others (Migliori et al., 2019; Migliori
et al., 2018; World Health Organization, 2019).
From a programmatic perspective all the necessary components
required to diagnose and treat MDR-TB should work adequately
within a coherent National Strategic Plan (World Health Organi-
zation, 2015b): quality-controlled laboratory network; drug
procurement; clinical services; surveillance, and monitoring and
evaluation.
Conclusions
Although a significant advance in diagnosis and treatment has
been achieved with the existing (and new) rapid molecular
diagnostics, as well as with the BPaL shortened regimen, further
research investments are necessary on fast patient triage and all-
oral shorter and better tolerated regimens. On top of further
improving the existing diagnostic, treatment and prevention tools,
universal access and correct programmatic use are needed in all
settings, in order to implement the three pillars of the End TB
strategy (1. Integrated, patient-centred care and prevention; 2.
Bold policies and support systems; 3. Intensified research and
innovation) and meet its goal and targets.
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